An animal PET scanner using flat-panel position-sensitive PMTs.

OBJECTIVE: To design, build, and evaluate an animal PET scanner, which can be used with non-human primates under conscious condition, incorporating flat-panel position-sensitive photomultiplier tubes (PS-PMTs). METHODS: The system contains 30 detector modules, each having two PS-PMTs and 16×18 lutetium­yttrium oxyortho-silicate scintillation crystal arrays. The system has 17,280 crystals (480 per ring) arranged in 36 rings, with a diameter of 508 mm and axial extent of 108 mm. The gantry tilt mechanism enables PET studies to be performed on a monkey in the sitting position. Data can be acquired in either the 2D or 3D mode, with the slice collimators being retracted in the 3D mode. RESULTS: At the center of the field-of-view, radial resolution is 2.7 mm full width at half maximum (FWHM) and tangential resolution is 2.4 mm FWHM, while axial resolution is 2.5 mm FWHM for direct slices and 2.7 mm FWHM for cross slices. Scatter fraction, count rate capability, and sensitivity were evaluated using a cylindrical phantom 10 cm in diameter. The noise equivalent count rate in the 3D mode is equivalent to that in the 2D mode at a three times higher radioactivity level. Total system sensitivity is 1.3 kcps/(kBq/mL) in 2D mode and 7.4 kcps/(kBq/mL) in the 3D mode. Animal studies with a monkey were performed to evaluate the imaging capabilities of the scanner. CONCLUSION: The new PET scanner will be a useful research tool with non-human primates for pre-clinical drug development.

Evaluation of O-[(18)F]fluoromethyl-D-tyrosine as a radiotracer for tumor imaging with positron emission tomography.

O-[(18)F]Fluoromethyl-D-tyrosine (D-[(18)F]FMT) has been reported as a potential tumor-detecting agent for positron emission tomography (PET). However, the reason why D-[(18)F]FMT is better than L-[(18)F]FMT is unclear. To clarify this point, we examined the mechanism of their transport and their suitability for tumor detection. The stereo-selective uptake and release of enantiomerically pure D- and L-[(18)F]FMT by rat C6 glioma cells and human cervix adenocarcinoma HeLa cells were examined. The results of a competitive inhibition study using various amino acids and a selective inhibitor for transport system L suggested that D-[(18)F]FMT, as well as L-[(18)F]FMT, was transported via system L, the large neutral amino acid transporter, possibly via LAT1. The in vivo distribution of both [(18)F]FMT and [(18)F]FDG in tumor-bearing mice and rats was imaged with a high-resolution small-animal PET system. In vivo PET imaging of D-[(18)F]FMT in mouse xenograft and rat allograft tumor models showed high contrast with a low background, especially in the abdominal and brain region. The results of our in vitro and in vivo studies indicate that L-[(18)F]FMT and D-[(18)F]FMT are specifically taken up by tumor cells via system L. D-[(18)F]FMT, however, provides a better tumor-to-background contrast with a tumor/background (contralateral region) ratio of 2.741 vs. 1.878 with the L-isomer, whose difference appears to be caused by a difference in the influence of extracellular amino acids on the uptake and excretion of these two isomers in various organs. Therefore, D-[(18)F]FMT would be a more powerful tool as a tumor-detecting agent for PET, especially for the imaging of a brain cancer and an abdominal cancer.